|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5652122A
(en)
|
1989-12-21 |
1997-07-29 |
Frankel; Alan |
Nucleic acids encoding and methods of making tat-derived transport polypeptides
|
|
US5804604A
(en)
|
1989-12-21 |
1998-09-08 |
Biogen, Inc. |
Tat-derived transport polypeptides and fusion proteins
|
|
JP3949711B2
(ja)
|
1990-02-26 |
2007-07-25 |
ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ |
昆虫ステロイドレセプターｄｎａ配列の同定及び発現
|
|
GB9206318D0
(en)
|
1992-03-24 |
1992-05-06 |
Cambridge Antibody Tech |
Binding substances
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5962255A
(en)
|
1992-03-24 |
1999-10-05 |
Cambridge Antibody Technology Limited |
Methods for producing recombinant vectors
|
|
WO1993011236A1
(en)
|
1991-12-02 |
1993-06-10 |
Medical Research Council |
Production of anti-self antibodies from antibody segment repertoires and displayed on phage
|
|
US5364791A
(en)
|
1992-05-14 |
1994-11-15 |
Elisabetta Vegeto |
Progesterone receptor having C. terminal hormone binding domain truncations
|
|
EP0745121B1
(en)
|
1992-05-14 |
2007-06-20 |
Baylor College Of Medicine |
Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
|
|
US6432652B1
(en)
|
1992-08-13 |
2002-08-13 |
The Regents Of The University Of California |
Methods of screening modulators of opioid receptor activity
|
|
JP4208960B2
(ja)
|
1992-08-13 |
2009-01-14 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
オピオイドレセプター遺伝子
|
|
US20020061554A1
(en)
|
1992-08-13 |
2002-05-23 |
Evans Christopher J. |
Orphan opioid receptor and recombinant materials for its production
|
|
EP0672142B1
(en)
|
1992-12-04 |
2001-02-28 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
|
US5814618A
(en)
|
1993-06-14 |
1998-09-29 |
Basf Aktiengesellschaft |
Methods for regulating gene expression
|
|
US5464758A
(en)
|
1993-06-14 |
1995-11-07 |
Gossen; Manfred |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
|
GB9313509D0
(en)
|
1993-06-30 |
1993-08-11 |
Medical Res Council |
Chemisynthetic libraries
|
|
SE9304060D0
(sv)
|
1993-12-06 |
1993-12-06 |
Bioinvent Int Ab |
Sätt att selektera specifika bakteriofager
|
|
US5962637A
(en)
|
1994-06-03 |
1999-10-05 |
Microbiological Research Authority |
Toxin assay
|
|
GB9411138D0
(en)
*
|
1994-06-03 |
1994-07-27 |
Microbiological Res Authority |
Toxin assay
|
|
US6495518B1
(en)
|
1994-06-13 |
2002-12-17 |
Vanderbilt University |
Method for importing biologically active molecules into cells
|
|
US5807746A
(en)
|
1994-06-13 |
1998-09-15 |
Vanderbilt University |
Method for importing biologically active molecules into cells
|
|
GB9500851D0
(en)
|
1995-01-17 |
1995-03-08 |
Bionvent International Ab |
Method of selecting specific bacteriophages
|
|
GB9508204D0
(en)
*
|
1995-04-21 |
1995-06-07 |
Speywood Lab Ltd |
A novel agent able to modify peripheral afferent function
|
|
FR2739621B1
(fr)
|
1995-10-05 |
1997-12-05 |
Centre Nat Rech Scient |
Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
|
|
US6072041A
(en)
|
1996-06-03 |
2000-06-06 |
Case Western Reserve University |
Fusion proteins for protein delivery
|
|
GB9617671D0
(en)
|
1996-08-23 |
1996-10-02 |
Microbiological Res Authority |
Recombinant toxin fragments
|
|
DE19702280A1
(de)
|
1997-01-23 |
1998-07-30 |
Bosch Gmbh Robert |
Verfahren zur Regelung der Leistungsverstärkung
|
|
EP0975370B9
(en)
|
1997-05-21 |
2004-11-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Composition and method for enhancing transport across biological membranes
|
|
US6248558B1
(en)
|
1998-03-31 |
2001-06-19 |
Vanderbilt University |
Sequence and method for genetic engineering of proteins with cell membrane translocating activity
|
|
GB9818548D0
(en)
|
1998-08-25 |
1998-10-21 |
Microbiological Res Authority |
Treatment of mucas hypersecretion
|
|
EP1137664A2
(en)
|
1998-12-10 |
2001-10-04 |
Washington University |
Protein transduction system and methods of use thereof
|
|
US6776990B2
(en)
|
1999-04-08 |
2004-08-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pancreatitis
|
|
WO2000064533A1
(en)
|
1999-04-22 |
2000-11-02 |
Cygnus, Inc. |
Methods and devices for removing interfering species
|
|
US7034132B2
(en)
|
2001-06-04 |
2006-04-25 |
Anderson David W |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
KR100876060B1
(ko)
|
1999-08-25 |
2008-12-26 |
알러간, 인코포레이티드 |
활성화가능한 재조합 신경독
|
|
US20030180289A1
(en)
|
1999-09-23 |
2003-09-25 |
Foster Keith Alan |
Inhibition of secretion from non-neuronal cells
|
|
US20030008813A1
(en)
|
1999-12-17 |
2003-01-09 |
Felgner Philip L. |
Intracellular protein delivery compositions and methods of use
|
|
GB9930519D0
(en)
|
1999-12-24 |
2000-02-16 |
Phogen Limited |
Uses of transport proteins
|
|
US7138127B1
(en)
|
2000-01-19 |
2006-11-21 |
Allergan, Inc. |
Clostridial toxin derivatives and methods for treating pain
|
|
US6500436B2
(en)
|
2000-01-19 |
2002-12-31 |
Allergan, Inc. |
Clostridial toxin derivatives and methods for treating pain
|
|
US7034121B2
(en)
|
2000-01-27 |
2006-04-25 |
Genetics Institue, Llc |
Antibodies against CTLA4
|
|
US6903187B1
(en)
*
|
2000-07-21 |
2005-06-07 |
Allergan, Inc. |
Leucine-based motif and clostridial neurotoxins
|
|
US20040219619A1
(en)
|
2000-07-21 |
2004-11-04 |
Ester Fernandez-Salas |
Methods of identifying compounds that alter toxin persistence and/or protease activity
|
|
EP1305333A4
(en)
|
2000-07-31 |
2006-04-12 |
Active Motif |
PEPTIDE-MEDIATED DELIVERY OF MOLECULES IN CELLS
|
|
EE04529B1
(et)
|
2001-03-16 |
2005-08-15 |
Tartu �likool |
Termofiilne mikroorganismi tüvi Bacillus coagulans SIM-7 DSM 14043 ja meetod L(+)-laktaadi tootmiseks fermenteeritavatest suhkrutest ja nende segudest nimetatud mikroorganismi tüve abil
|
|
US7332567B2
(en)
|
2001-08-28 |
2008-02-19 |
Allergan, Inc. |
Fret protease assays for clostridial toxins
|
|
US7374896B2
(en)
*
|
2001-08-28 |
2008-05-20 |
Allergan, Inc. |
GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
|
|
US8022172B2
(en)
|
2001-08-28 |
2011-09-20 |
Allergan, Inc. |
Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
|
|
US7208285B2
(en)
|
2001-08-28 |
2007-04-24 |
Allergan, Inc. |
Fret protease assays for botulinum serotype A/E toxins
|
|
US20040057958A1
(en)
|
2002-05-17 |
2004-03-25 |
Waggoner David W. |
Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
|
|
RU2230325C2
(ru)
*
|
2002-08-15 |
2004-06-10 |
Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации |
Способ приготовления очищенного препарата ботулинического токсина типа а
|
|
US7183066B2
(en)
|
2002-09-27 |
2007-02-27 |
Allergan, Inc. |
Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
|
|
US7166692B2
(en)
|
2003-03-04 |
2007-01-23 |
Canbrex Bio Science Walkersville, Inc. |
Intracellular delivery of small molecules, proteins, and nucleic acids
|
|
GB0321344D0
(en)
|
2003-09-11 |
2003-10-15 |
Health Prot Agency |
Re-targeted toxin conjugates
|
|
JP4262072B2
(ja)
|
2003-12-05 |
2009-05-13 |
株式会社日立製作所 |
自動車用補助機器制御装置
|
|
WO2005076785A2
(en)
*
|
2003-12-19 |
2005-08-25 |
Wisconsin Alumni Research Foundation |
Method and compositions for detecting botulinum neurotoxin
|
|
WO2005082096A2
(en)
|
2004-02-24 |
2005-09-09 |
Allergan, Inc. |
Botulinum toxin screening assays
|
|
US7811584B2
(en)
|
2004-06-30 |
2010-10-12 |
Allergan, Inc. |
Multivalent clostridial toxins
|
|
US7514088B2
(en)
|
2005-03-15 |
2009-04-07 |
Allergan, Inc. |
Multivalent Clostridial toxin derivatives and methods of their use
|
|
WO2006011966A1
(en)
|
2004-06-30 |
2006-02-02 |
Allergan, Inc. |
Optimizing expression of active botulinum toxin type e
|
|
EP1773874B1
(en)
|
2004-08-04 |
2012-10-24 |
Allergan, Inc. |
Optimizing expression of active botulinum toxin type a
|
|
EP1784420B1
(en)
*
|
2004-09-01 |
2008-12-03 |
Allergan, Inc. |
Degradable clostridial toxins
|
|
US7399607B2
(en)
|
2004-09-22 |
2008-07-15 |
Allergan, Inc. |
Fluorescence polarization assays for determining clostridial toxin activity
|
|
WO2006042149A2
(en)
|
2004-10-06 |
2006-04-20 |
Allergan, Inc. |
Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
|
|
US7659092B2
(en)
|
2004-12-01 |
2010-02-09 |
Syntaxin, Ltd. |
Fusion proteins
|
|
GB0426394D0
(en)
*
|
2004-12-01 |
2005-01-05 |
Health Prot Agency |
Fusion proteins
|
|
EP1877073B1
(en)
|
2004-12-01 |
2013-09-25 |
The Secretary of State for Health |
Non-cytotoxic protein conjugates
|
|
US8603779B2
(en)
*
|
2004-12-01 |
2013-12-10 |
Syntaxin, Ltd. |
Non-cytotoxic protein conjugates
|
|
GB0426397D0
(en)
|
2004-12-01 |
2005-01-05 |
Health Prot Agency |
Fusion proteins
|
|
US8512984B2
(en)
*
|
2004-12-01 |
2013-08-20 |
Syntaxin, Ltd. |
Non-cytotoxic protein conjugates
|
|
CA2595115C
(en)
|
2004-12-01 |
2014-01-21 |
Health Protection Agency |
Fusion proteins for treating, preventing or ameliorating pain
|
|
US8021859B2
(en)
*
|
2005-03-15 |
2011-09-20 |
Allergan, Inc. |
Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
|
|
EP1869459B1
(en)
|
2005-04-05 |
2010-06-09 |
Allergan, Inc. |
Lipophilic dye-based fret assays for clostridial toxin activity
|
|
US8796429B2
(en)
|
2006-05-31 |
2014-08-05 |
Lpath, Inc. |
Bioactive lipid derivatives, and methods of making and using same
|
|
EP2038299A2
(en)
|
2006-07-11 |
2009-03-25 |
Allergan, Inc. |
Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
|
|
CA2658260A1
(en)
|
2006-07-11 |
2008-01-17 |
Allergan, Inc. |
Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
|
|
BR122012027456A2
(pt)
*
|
2008-03-14 |
2015-07-14 |
Allergan Inc |
Composição farmacêutica compreendendo sorotipo de neurotoxina botulínica a
|
|
KR101604515B1
(ko)
*
|
2008-03-14 |
2016-03-17 |
알러간, 인코포레이티드 |
면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
|
|
PT3281953T
(pt)
*
|
2009-03-13 |
2020-01-15 |
Allergan Inc |
Ensaios de base imunológica da actividade de endopeptidase redireccionada
|